Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Daily News

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

Caitlin E. Cox

September 16, 2024

News Daily News

Early, Intense GDMT Improves Decongestion in Acute HF: STRONG-HF

Todd Neale

July 19, 2024

News Daily News

Kidney Events High in Older Patients After HF Hospitalization

L.A. McKeown

May 30, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Daily News

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

L.A. McKeown

October 10, 2023

News Daily News

Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF

Todd Neale

July 03, 2023

News Daily News

NSAIDs Tied to HF Hospitalization in Patients With Diabetes

L.A. McKeown

April 10, 2023

News Daily News

Top Heart Failure News of 2022

Shelley Wood

January 04, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

Todd Neale

July 09, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Daily News

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

L.A. McKeown

January 11, 2021

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

Advertisement

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

Early, Intense GDMT Improves Decongestion in Acute HF: STRONG-HF

Kidney Events High in Older Patients After HF Hospitalization

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF

NSAIDs Tied to HF Hospitalization in Patients With Diabetes

Top Heart Failure News of 2022

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Guideline-Directed Therapies Underused in Frail HF Patients

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

FDA Approves Dapagliflozin for CKD Patients

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content